Advertisement

Letter regarding “Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials”

  • Author Footnotes
    1 Zheng Li and Yue Hu contributed equally to this work.
    Zheng Li
    Footnotes
    1 Zheng Li and Yue Hu contributed equally to this work.
    Affiliations
    Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China
    Search for articles by this author
  • Author Footnotes
    1 Zheng Li and Yue Hu contributed equally to this work.
    Yue Hu
    Footnotes
    1 Zheng Li and Yue Hu contributed equally to this work.
    Affiliations
    Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
    Search for articles by this author
  • Qiang Li
    Correspondence
    Corresponding author at: Institute of Modern Physics, Chinese Academy of Sciences, 509 Nanchang Road, Lanzhou 730000, China.
    Affiliations
    Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China
    Search for articles by this author
  • Author Footnotes
    1 Zheng Li and Yue Hu contributed equally to this work.
Published:October 03, 2022DOI:https://doi.org/10.1016/j.radonc.2022.09.018
      With great interest, we read the article by Viani et al. [
      • Viani G.A.
      • Gouveia A.G.
      • Matsuura F.K.
      • Jacinto A.A.
      • Moraes F.Y.
      Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials.
      ] recently published in the Green Journal in August 2022. The authors conducted a meta-analysis to synthesize the randomized controlled trials (RCTs) for assessing once-daily versus twice-daily chemoradiation for limited-stage small-cell lung cancer. It is necessary for corresponding clinical decision-makings because meta-analysis could provide more determinate evidence. However, some issues should be addressed to reduce the risk of potential biases and obtain more convincing results.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Viani G.A.
        • Gouveia A.G.
        • Matsuura F.K.
        • Jacinto A.A.
        • Moraes F.Y.
        Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials.
        Radiother Oncol. 2022; 173: 41-48https://doi.org/10.1016/j.radonc.2022.01.032
      1. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from http://www.training.cochrane.org/handbook.

        • Guyatt G.H.
        • Oxman A.D.
        • Kunz R.
        • Woodcock J.
        • Brozek J.
        • Helfand M.
        • et al.
        GRADE guidelines: 7. Rating the quality of evidence–inconsistency.
        J Clin Epidemiol. 2011; 64: 1294-1302https://doi.org/10.1016/j.jclinepi.2011.03.017
        • Stewart L.
        • Moher D.
        • Shekelle P.
        Why prospective registration of systematic reviews makes sense.
        Syst Rev. 2012; 1: 7https://doi.org/10.1186/2046-4053-1-7
        • Guyatt G.H.
        • Oxman A.D.
        • Vist G.
        • Kunz R.
        • Brozek J.
        • Alonso-Coello P.
        • et al.
        GRADE guidelines: 4. Rating the quality of evidence–study limitations (risk of bias).
        J Clin Epidemiol. 2011; 64: 407-415https://doi.org/10.1016/j.jclinepi.2010.07.017
        • Faivre-Finn C.
        • Snee M.
        • Ashcroft L.
        • Appel W.
        • Barlesi F.
        • Bhatnagar A.
        • et al.
        Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
        Lancet Oncol. 2017; 18: 1116-1125https://doi.org/10.1016/s1470-2045(17)30318-2
        • Qiu B.
        • Li Q.
        • Liu J.
        • Huang Y.
        • Pang Q.
        • Zhu Z.
        • et al.
        Moderately Hypofractionated Once-Daily Compared With Twice-Daily Thoracic Radiation Therapy Concurrently With Etoposide and Cisplatin in Limited-Stage Small Cell Lung Cancer: A Multicenter, Phase II, Randomized Trial.
        Int J Radiat Oncol Biol Phys. 2021; 111: 424-435https://doi.org/10.1016/j.ijrobp.2021.05.003
        • Higgins J.P.
        • Altman D.G.
        • Gøtzsche P.C.
        • Jüni P.
        • Moher D.
        • Oxman A.D.
        • et al.
        The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
        BMJ. 2011; 343: d5928https://doi.org/10.1136/bmj.d5928
        • Guyatt G.H.
        • Oxman A.D.
        • Montori V.
        • Vist G.
        • Kunz R.
        • Brozek J.
        • et al.
        GRADE guidelines: 5. Rating the quality of evidence–publication bias.
        J Clin Epidemiol. 2011; 64: 1277-1282https://doi.org/10.1016/j.jclinepi.2011.01.011
        • Guyatt G.H.
        • Oxman A.D.
        • Vist G.E.
        • Kunz R.
        • Falck-Ytter Y.
        • Alonso-Coello P.
        • et al.
        GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.
        BMJ. 2008; 336: 924-996https://doi.org/10.1136/bmj.39489.470347.AD
        • McAuley L.
        • Pham B.
        • Tugwell P.
        • Moher D.
        Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses?.
        Lancet. 2000; 356: 1228-1231https://doi.org/10.1016/s0140-6736(00)02786-0
        • Schild S.E.
        • Bonner J.A.
        • Shanahan T.G.
        • Brooks B.J.
        • Marks R.S.
        • Geyer S.M.
        • et al.
        Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.
        Int J Radiat Oncol Biol Phys. 2004; 59: 943-951https://doi.org/10.1016/j.ijrobp.2004.01.055
        • Bogart J.A.
        • Wang X.F.
        • Masters G.A.
        • Gao J.H.
        • Komaki R.
        • Kuzma C.S.
        • et al.
        Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538.
        J Clin Oncol. 2021; 39: 8505https://doi.org/10.1200/JCO.2021.39.15_suppl.8505

      Linked Article